American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity
- Resource Type
- Authors
- Nicole Fett; James T. Rosenbaum; Ronald B. Melles; Julianna Desmarais; Victoria P. Werth; Michael F. Marmor; Karen H. Costenbader; Ellen M. Ginzler; Susan M. Goodman; Gabriela Schmajuk; James R. O'Dell
- Source
- Arthritis & Rheumatology. 73:908-911
- Subject
- medicine.medical_specialty
Deprescriptions
genetic structures
Immunology
MEDLINE
Dermatology
Disease
03 medical and health sciences
0302 clinical medicine
Retinal Diseases
Rheumatology
Internal medicine
medicine
Humans
Mass Screening
Immunology and Allergy
Intensive care medicine
Societies, Medical
Mass screening
030203 arthritis & rheumatology
business.industry
Hydroxychloroquine
eye diseases
Annual Screening
Ophthalmology
Retinal toxicity
Antirheumatic Agents
030221 ophthalmology & optometry
Visual Field Tests
business
Tomography, Optical Coherence
medicine.drug
- Language
- ISSN
- 2326-5205
2326-5191
Four major medical societies involved with hydroxychloroquine (HCQ) therapy concur on the need for common principles and cooperation to minimize the risk of ocular toxicity. At a daily dosage of ≤5 mg/kg/day actual body weight, the risk of retinal toxicity from HCQ is